BiotechTube
NanoCytomics

NanoCytomics

San Diego, United States· Est.
nano-cytomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

NanoCytomics is a private, pre-revenue diagnostics company leveraging its proprietary PWS (Partial Wave Spectroscopy) Nanocytology platform to create non-invasive cancer risk stratification tests. Founded by a team of leading academics, the company aims to deploy simple sample collection in primary care settings, with results guiding the need for more invasive, gold-standard diagnostics. Its first Laboratory Developed Test (LDT) was anticipated for 2018, targeting significant improvements in early cancer detection and healthcare cost reduction.

Oncology

Technology Platform

Proprietary PWS (Partial Wave Spectroscopy) Nanocytology platform designed to detect nanoscale architectural changes in cells from non-invasive samples (e.g., buccal swabs) for early cancer risk stratification.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive unmet need for non-invasive, low-cost, and highly compliant cancer screening creates a significant market opportunity.
By positioning its test in the primary care setting for risk stratification, NanoCytomics can improve early detection rates and generate substantial cost savings for the healthcare system by reducing unnecessary invasive procedures.

Risk Factors

Key risks include the need for extensive clinical validation to prove utility, challenges in achieving physician adoption and insurance reimbursement in a crowded diagnostics market, and potential competition from other early detection technologies like liquid biopsies.

Competitive Landscape

NanoCytomics competes in the rapidly evolving multi-cancer early detection (MCED) and risk stratification space, which includes large public companies like Exact Sciences and Guardant Health, as well as numerous other startups. Its differentiation lies in the PWS technology's focus on nanoscale cellular architecture and its intended use in primary care for risk stratification prior to definitive diagnostics.

More companies in Diagnostics & Precision Medicine →More companies in United States →